Janux Therapeutics

Summary
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

History

Janux Therapeutics was founded in 2019 with the goal of revolutionizing the treatment of cancer and other diseases. We are focused on discovering, developing and commercializing novel therapies for the most challenging malignant and infectious diseases. We strive to create treatments that have a meaningful impact on patient outcomes and quality of life.


Mission
To transform the lives of patients by providing innovative and effective treatments for cancer and other diseases.

Vision
To be the leading biopharmaceutical company in the fight against cancer and other diseases.

Key Team

Mr. Tommy Diraimondo Ph.D. (Sr. Director of Research)

Ms. Brenda Van Vreeswyk (Head of HR)

Mr. Andy Hollman Meyer (Chief Bus. Officer)

Mr. Byron Robinson J.D., Ph.D. (Chief Strategy Officer)

Mr. Charles M. Winter (Sr. VP of Chemistry, Manufacturing & Controls)


Recognition and Awards
Janux Therapeutics was recently named one of Forbes' Most Promising Startups of 2021.

References
Janux Therapeutics
Leadership team

Dr. David Alan Campbell Ph.D. (Pres, CEO & Director)

Dr. Wayne Godfrey M.D. (Chief Medical Officer)

Mr. Tighe M. Reardon C.F.A., CPA, CPA (Acting Chief Financial Officer)

Products/ Services
Biotechnology, Health Diagnostics, Pharmaceutical, Therapeutics
Headquarters
La Jolla, California, United States
Established
2017
Company Registration
SEC CIK number: 0001817713
Revenue
5M - 20M
Traded as
JANX
Social Media
Sat Feb 24 2024
About

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with
Logo

Copyright 2023 © businessabc powered by ztudium